



Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020

July 9, 2020

SEATTLE, July 09, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter ended June 30, 2020 after market close on Monday, August 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.

Investor Contact:

Karina Calzadilla, Vice President, Investor Relations
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

Media Contact:

Beth Keshishian
media@adaptivebiotech.com



Source: Adaptive Biotechnologies